(Q43764750)

26 November 2017

0 references

Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy? (English)

1 reference

26 November 2017

author

Françoise Kraeber-Bodéré

series ordinal

2

1 reference

26 November 2017

Jacques Barbet

3

0 references

author name string

Caroline Rousseau

series ordinal

1

1 reference

26 November 2017

Jean-François Chatal

series ordinal

4

1 reference

26 November 2017

publication date

1 September 2013

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

26 November 2017

published in

1 reference

26 November 2017

volume

40

1 reference

26 November 2017

issue

9

1 reference

26 November 2017

page(s)

1373-1376

1 reference

Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2469-9

Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten

21 January 2018

1 reference

12 December 2020

Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial

1 reference

12 December 2020

High Frequency of Bone/Bone Marrow Involvement in Advanced Medullary Thyroid Cancer

1 reference

12 December 2020

Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial

1 reference

12 December 2020

Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.

1 reference

12 December 2020

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody

1 reference

12 December 2020

Selection of first-line therapy for advanced follicular lymphoma

1 reference

12 December 2020

Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections

1 reference

12 December 2020

Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten

1 reference

12 December 2020

10.1007/S00259-013-2469-9

Identifiers

DOI

1 reference

26 November 2017

1 reference